The slides were reviewed based on the presence or absence of the following characteristics: tumour-stroma cleft formation, ulceration, epithelial primitive structures, small keratinous cysts, inflammatory response, mitosis, Hydrochlorothiazide necrotic Lafutidine tumour cells, papillary mesenchymal bodies, stromal oedema and peritumoral mucin production. Eventually, 35 TE were found to unambiguously fit the criteria for classic TE and these were used for the analysis, together with 45 BCC. All of the used samples and corresponding data were de-linked and anonymised. Usage of tissue samples was approved by the Maastricht Pathology Tissue Collection scientific committee. The HIF and mTORC1 signalling pathways play crucial roles in many malignancies. To the best of our knowledge, we are the first to perform a systematic analysis of HIF and mTORC1 signalling in both BCC and TE. Although TE showed significantly more expression of CAIX, Glut1 and PHD2, this was only in the proportion of samples with high expression levels of at least 80% and thus not likely to reflect a genuine difference between the two tumour types. The correlations found between components of HIF signalling and the mTORC1 pathway are in line with known crosstalk between both pathways. GLUT1, CAIX and BNIP3 are the most important readouts for HIF1a signalling and our data show positivity of all three target genes in the majority of both BCC and TE. Positive VEGF-A staining patterns were found in the endothelial cells of blood vessels as well as in BCC/TE tumour cells. However, VEGF-A expression was not specifically tumour related, since some weak staining was also noted in the basal cell layer of epidermis adjacent to the tumours. These low and weak VEGF-A expression levels are in agreement with earlier studies in BCC and other benign and malignant skin tumours and might be explained by the low levels of mTORC1 expression found, since recent evidence indicates that mTORC1 can drive VEGF-A expression.It also fits with the low metastatic behaviour of BCC. Accordingly, strong VEGF-A expression is observed in the more aggressive and potentially metastasizing squamous cell carcinoma and melanoma.